On August 19, 2026, Merck and Moderna announced that a personalized mRNA cancer vaccine, given with the immunotherapy Keytruda after surgery, kept melanoma from coming back longer than Keytruda alone in a phase 3 trial of 1,137 patients. Their news release says the INTerpath-001 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. It is the first positive phase 3 result for an mRNA-based cancer therapy.
The companies did not release a single efficacy number.
Key takeaways
- The trial hit its main goal, but Merck and Moderna published no effect sizes, no survival curves, and no peer-reviewed paper.
- The “49% reduction in recurrence” figure circulating online comes from the earlier phase 2b KEYNOTE-942 trial, not from this trial.
- Overall survival, the endpoint that matters most, is still being measured. The trial is continuing.
What the companies announced
INTerpath-001 enrolled 1,137 patients with completely resected stage IIB-IV cutaneous melanoma who had not had prior systemic therapy. After surgery, they were randomized 2 to 1 to the vaccine, called intismeran autogene, at 1 mg every three weeks for up to nine doses plus Keytruda, or to Keytruda alone. Treatment ran for roughly a year.
The result came at a pre-specified interim analysis, a planned early look at the data. The release states the combination “demonstrated statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone.” Safety profiles were consistent with earlier studies, “with no new safety signals observed.”
The vaccine is built for each patient. A tumor sample is sequenced for its specific mutations, and the therapy is made as synthetic mRNA coding for up to 34 of those neoantigens, so the immune system learns to recognize that person’s cancer.
The trial is continuing in order to evaluate overall survival. The data will be presented at an upcoming international medical meeting and shared with regulators.
The numbers being quoted are from a smaller study
Merck’s release cites 5-year follow-up from the phase 2b KEYNOTE-942 trial, which found a 49% lower risk of recurrence or death (hazard ratio 0.51) and a 59% lower risk of distant metastasis or death (hazard ratio 0.411). The uncertainty is wide: the first is very likely between 11% and 71% lower (95% CI, 0.294 to 0.887), the second between 16% and 80% lower (95% CI, 0.200 to 0.843).
Those numbers are being repeated as if they described the new trial. They do not.
Dr. Kumar’s take
Recurrence-free survival is a real win, not a soft one. For someone who has had a melanoma cut out, more time without the cancer returning is time worth having. Distant metastasis-free survival moving the same way is the more reassuring signal, because spread to other organs is what usually kills people with melanoma.
It is still not the same as living longer. A treatment can delay a recurrence on a scan without changing when a person dies, which is why overall survival is still being collected here. Until it reads out, the honest summary is that the cancer stayed away longer, not that more people survived.
The bigger question is what a bespoke drug does to real-world care. Dr. Janice Mehnert, an investigator on the earlier trial, told NBC News that making an individualized shot “takes several weeks.” Weeks of sequencing and manufacturing, per person, is a different supply chain than pulling a vial off a shelf, and no price has been announced.
The platform result is the other headline. mRNA was built to be reprogrammable, and this is the first phase 3 evidence that reprogramming it against a person’s own tumor changes an outcome.
What it means for you
Intismeran is investigational. It is not approved, not available outside of trials, and no filing date has been announced. Anyone with resected stage IIB-IV melanoma who wants access should ask an oncologist about the INTerpath program, which spans nine phase 2 and phase 3 trials across melanoma, lung, bladder and kidney cancer.
For everyone else, wait for the medical meeting presentation, where the actual curves and numbers will be shown, and treat any percentage quoted before then with suspicion. Vaccines earning hard cancer outcomes is a pattern worth tracking, as with the HPV vaccine data in boys and young men.
Melanoma prevention has not changed. Sun protection and skin checks still do more for most people than anything in this announcement.